Roniciclib

Drug Profile

Roniciclib

Alternative Names: BAY 1000394; CDK-I; Pan-CDK inhibitor

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Alcohols; Antineoplastics; Cyclopropanes; Fluorine compounds; Imines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Small cell lung cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Bayer completes a phase I trial for Solid tumours in USA, France and Germany (NCT01188252)
  • 30 Jun 2016 Bayer completes a phase I clinical trial in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Hungary (PO) (NCT02390154)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top